NASD · Healthcare · Biotechnology · Israel
Evogene Ltd is a micro cap company (market value under $300 million) in the Biotechnology industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Evogene Ltd stock.
Slightly undervalued: intrinsic value $0.41 per share, market price $0.37, margin of safety 10.4% (as of 2026-10-30).
Its liquidation floor, current assets minus every liability, values the shares at $0.41; the price of $0.37 is 10% below that value.
Leak Score: 58/100 on 8 of 12 signals (Weak Signal).
19 more in this industry show a wider margin of safety.
EVGN is slightly undervalued (as of the 2026-10-30 close). Its liquidation floor, current assets minus every liability, values the shares at $0.41; the price of $0.37 is 10% below that value.
$0.41 per share (as of the 2026-10-30 close), against a market price of $0.37. That is a margin of safety of 10.4%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
58 out of 100, which we rate "Weak Signal", on 8 of 12 value investing signals.